"Muromonab-CD3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Anti-CD3 monoclonal antibody that exerts immunosuppressive effects by inducing peripheral T-cell depletion and modulation of the T-cell receptor complex (CD3/Ti).
| Descriptor ID |
D016853
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.075.570 D12.776.124.486.485.114.619.393.570 D12.776.124.790.651.114.224.075.570 D12.776.124.790.651.114.619.393.570 D12.776.377.715.548.114.224.284.570 D12.776.377.715.548.114.619.393.570
|
| Concept/Terms |
Muromonab-CD3- Muromonab-CD3
- Muromonab CD3
- OKT3
- Monoclonal Antibody OKT3
|
Below are MeSH descriptors whose meaning is more general than "Muromonab-CD3".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Murine-Derived [D12.776.124.486.485.114.224.075]
- Muromonab-CD3 [D12.776.124.486.485.114.224.075.570]
- Immunoglobulin Isotypes [D12.776.124.486.485.114.619]
- Immunoglobulin G [D12.776.124.486.485.114.619.393]
- Muromonab-CD3 [D12.776.124.486.485.114.619.393.570]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Murine-Derived [D12.776.124.790.651.114.224.075]
- Muromonab-CD3 [D12.776.124.790.651.114.224.075.570]
- Immunoglobulin Isotypes [D12.776.124.790.651.114.619]
- Immunoglobulin G [D12.776.124.790.651.114.619.393]
- Muromonab-CD3 [D12.776.124.790.651.114.619.393.570]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Murine-Derived [D12.776.377.715.548.114.224.284]
- Muromonab-CD3 [D12.776.377.715.548.114.224.284.570]
- Immunoglobulin Isotypes [D12.776.377.715.548.114.619]
- Immunoglobulin G [D12.776.377.715.548.114.619.393]
- Muromonab-CD3 [D12.776.377.715.548.114.619.393.570]
Below are MeSH descriptors whose meaning is more specific than "Muromonab-CD3".
This graph shows the total number of publications written about "Muromonab-CD3" by people in this website by year, and whether "Muromonab-CD3" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 4 | 0 | 4 |
| 1994 | 3 | 0 | 3 |
| 1995 | 2 | 4 | 6 |
| 1996 | 4 | 4 | 8 |
| 1997 | 2 | 2 | 4 |
| 1998 | 1 | 3 | 4 |
| 1999 | 1 | 2 | 3 |
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Muromonab-CD3" by people in Profiles.
-
Mature neutrophils suppress T cell immunity in ovarian cancer microenvironment. JCI Insight. 2019 03 07; 4(5).
-
Early discontinuation of steroids is safe and effective in pediatric kidney transplant recipients. Pediatr Transplant. 2005 Aug; 9(4):456-63.
-
Induction therapy with interleukin-2 receptor antagonist after intestinal transplantation is associated with reduced acute cellular rejection and improved renal function. Transplant Proc. 2004 Mar; 36(2):331-2.
-
Simultaneous pancreas-kidney transplant from living related donor: a single-center experience. Transplantation. 2003 Aug 15; 76(3):547-52.
-
Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheumatol. 2002 Sep; 29(9):1907-13.
-
Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin, and daclizumab. J Heart Lung Transplant. 2001 Dec; 20(12):1282-90.
-
The impact of positive T-cell lymphocytotoxic crossmatch on intestinal allograft rejection and survival. Transplant Proc. 2000 Sep; 32(6):1197-8.
-
Human fetal retinal pigment epithelium suppresses the activation of CD4(+) and CD8(+) T-cells. Graefes Arch Clin Exp Ophthalmol. 1999 Nov; 237(11):934-9.
-
Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation. 1999 Sep 15; 68(5):608-16.
-
Efficacy of tacrolimus in the treatment of refractory rejection in heart and lung transplant recipients. J Heart Lung Transplant. 1999 May; 18(5):448-55.